Breast Cancer Liquid Biopsy Market: Global Industry Analysis and Forecast (2022-2029)

Breast Cancer Liquid Biopsy Market is anticipated to reach US$ 1.98 Bn. by 2029 from US$ 0.48 Bn. in 2021 at a CAGR of 19.2 % during a forecast period.

A breast cancer liquid biopsy is a simple and non-invasive alternative to surgical biopsies that allows physicians to discover several data about a tumor from a single blood sample. Cancer DNA traces in the blood can reveal which therapies are most likely to be beneficial for a certain patient. Breast cancer liquid biopsy may also improve therapy and patient clinical outcomes. Breast cancer liquid biopsy is very fragmented as a result of technological improvements and medical therapy breakthroughs.

To know about the Research Methodology:- Request Free Sample Report
Breast Cancer Liquid Biopsy Market Dynamics
Rising breast cancer prevalence, rising preference for non-invasive procedures, government and global health organization initiatives, technological advancements to augment market revenues, increasing emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the market. Increased patient awareness of breast cancer treatment, advantages of breast cancer liquid biopsy tests over traditional tests, increased adoption of liquid biopsy tests, a surge in pre-screening programs and next-generation sequencing (NGS) among healthcare professionals and a surge in demand for breast cancer liquid biopsy reagent kits are just a few of the factors driving the market growth.

In addition, the global increase in breast cancer incidence is one of the primary reasons driving the market growth. Breast cancer is the most common kind of cancer among women worldwide, according to the World Health Organization (WHO). Breast cancer affects over 2.1 million women each year, and it is the leading cause of cancer-related mortality among women. Breast cancer claimed the lives of an estimated 627,000 women in 2018, accounting for over 15% of all cancer deaths among women worldwide. According to Breast Cancer Care WA Incorporated, 19,371 Australian women were diagnosed with breast cancer in 2021, or about 53 per day, accounting for almost 14% of all new cancer cases diagnosed. Breast cancer is also the most frequent cancer in the United Kingdom, accounting for 15% of all new cancer cases, according to Cancer Research UK. Growing demand for improved minimally invasive therapy is the primary driver of the Breast Cancer Liquid Biopsy Market.

However, the market's growth is likely to be hampered by restrictions related to liquid biopsy testing, as well as a lack of access and understanding of breast cancer liquid biopsy in developing countries.
Breast Cancer Liquid Biopsy Market Segmentation Analysis
By Circulating Biomarker, Circulating tumor cells and cell-free DNA are a lucrative market segment among circulating biomarkers, and they are expected to hold a large part of the market in the future years. Technological advancements and medical treatment improvements are two reasons that have contributed to the market's growth. Because most diagnostic, prognostic, and therapy-predictive procedures aim to enhance the overall degree of personalization, the circulating biomarker segment is expected to continue to dominate the market over the forecast period.
Breast Cancer Liquid Biopsy Market Regional Insight:
North America dominated the worldwide Breast Cancer Liquid Biopsy Market in 2021, accounting for more than two-fifths of the market. Also, throughout the forecast period, this region is expected to have the quickest CAGR of 5.6 percent. This is due to reasons such as an increase in the frequency of breast cancer, physicians' and patients' demand for minimally invasive procedures, the availability of modern healthcare facilities with skilled medical experts, and an increase in the number of R&D activities.

Additionally, from 2021 to 2029, the market in Asia-Pacific is expected to grow at the quickest rate of 20.0 percent. The growth of the market is aided by an increase in the number of breast cancer patients, the advantages of breast cancer liquid biopsy testing over traditional tests, and improvements in healthcare facilities in this province.
Report Objectives:
• Landscape analysis of the Breast Cancer Liquid Biopsy Market
• competitive benchmarking
• Past and current status of the industry with the forecasted market size and trends
• Evaluation of potential key players that include market leaders, followers, and new entrants
• Technology trends
• Potential impact of micro-economic factors of the market
• External and Internal factors affecting market have been analysed

The report also helps in understanding the Breast Cancer Liquid Biopsy Market dynamics, structure by analysing the market segments and project the Breast Cancer Liquid Biopsy Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Breast Cancer Liquid Biopsy Market make the report investor’s guide.
Breast Cancer Liquid Biopsy Market Scope: Inquire before buying



Breast Cancer Liquid Biopsy Market


Report Coverage
Details


Base Year:
2021
Forecast Period:
2022-2029


Historical Data:
2017 to 2021
Market Size in 2021:
US $ 0.48 Bn.


Forecast Period 2022 to 2029 CAGR:
19.2  %
Market Size in 2029:
US $ 1.98 Bn.


 Segments Covered:
by Circulating Biomarker
• Circulating Tumour Cells (CTCs)
• Cell-free DNA (cfDNA)
• Extracellular Vehicles (EVs)
• Other Circulating Biomarkers


by End User
• Reference Laboratories
• Hospitals and Physician Laboratories
• Other End Users



Breast Cancer Liquid Biopsy Market, by Region
• North America
• Asia pacific
• Europe
• Middle East and Africa
• South America
Breast Cancer Liquid Biopsy Market Key Players
• QIAGEN N.V.
• Roche Diagnostics
• Bio-Rad Laboratories
• Myriad Genetics
• Menarini Silicon Biosystems
• Illumina
• Cynvenio Biosystems, Inc
• Genomic Health, Inc.
• Thermo Fisher Scientific Inc.
• Fluxion Biosciences, Inc
• Biodesix, Inc.
• Guardant Health, Inc.
• Isogen Life Science B.V.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd
• Menarini Silicon Biosystems
• Biocept, Inc.
• RainDance Technologies, Inc.
• FOUNDATION MEDICINE, INC.
• Sysmex Inostics
• Exosome Diagnostics
• Illumina, Inc
Frequently Asked Questions
1. What is the projected market size & growth rate of Breast Cancer Liquid Biopsy Market?
Ans- Breast Cancer Liquid Biopsy Market was valued at USD 0.48 Billion in 2022 and is projected to reach USD 1.98 Billion by 2029, growing at a CAGR of 19.2 % during the forecast period.

2. What are the key driving factors for the growth of Breast Cancer Liquid Biopsy Market?
Ans- Rising breast cancer prevalence, rising preference for non-invasive procedures, government and global health organization initiatives, technological advancements to augment market revenues, increasing emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the market.

3. Which Region accounted for the largest Breast Cancer Liquid Biopsy Market share?
Ans- North America dominated the worldwide Breast Cancer Liquid Biopsy Market in 2021, accounting for more than two-fifths of the market.

4. What makes Asia Pacific a Lucrative Market for Breast Cancer Liquid Biopsy Market?
Ans- The growth of the market is aided by an increase in the number of breast cancer patients, the advantages of breast cancer liquid biopsy testing over traditional tests, and improvements in healthcare facilities in this province.

5. What are the top players operating in Breast Cancer Liquid Biopsy Market?
Ans- QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini Silicon Biosystems, Illumina, Cynvenio Biosystems, Inc, and Genomic Health, Inc.